Xia Guo1, Qing Yang2, Jianjun Dong3, Lin Liao4, Weiwei Zhang5, Fupeng Liu6,7. 1. Intensive Care Unit, Tengnan Hospital of Zaozhuang Mining Group, Shandong, China. 2. Department of Medicine, Maternal and Child Care Service Centre of Tengzhou City, Shandong, China. 3. Department of Medicine, East Campus, Qilu Hospital, Shandong, China. 4. Department of Endocrinology, Qianfoshan Hospital of Shandong University, Shandong, China. 5. Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany. 6. Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany. Liufupengsdu@126.com. 7. Department of Endocrinology, Tengzhou Central People's Hospital, Shandong, China. Liufupengsdu@126.com.
Abstract
BACKGROUND AND OBJECTIVE: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel class of injectable antidiabetic drugs. Previous studies indicated that GLP-1RAs (exenatide and liraglutide) might increase the incidence of pancreatitis and pancreatic cancer. Here, we evaluated the clinical safety of once-weekly GLP-1RAs with respect to tumour risk. METHODS: Relevant studies were selected from ClinicalTrials.gov. Randomized controlled trials that reported the incidences of neoplasms were included in our research. Outcomes were calculated as the risk ratio using the Mantel-Haenszel method and fixed-effects model. RESULTS: Our analysis included 26 randomized controlled trials with 16,090 patients. Once-weekly GLP-1RAs did not increase the risk for tumours compared with other antidiabetic drugs [risk ratio (RR), 1.02; 95 % confidence interval (CI), 0.74-1.41; p = 0.91]; this finding was independent of the type of GLP-1RA administered (albiglutide, exenatide extended-release and dulaglutide) and duration of the trials (limited to ≥52 weeks). Subgroup analyses revealed that once-weekly GLP-1RAs did not increase tumour risk compared with placebos, exenatide and liraglutide, insulin or oral drugs. Additionally, once-weekly GLP-1RAs did not increase tumour risk in any tissue. CONCLUSIONS: Compared with other antidiabetic drugs, once-weekly GLP-1RAs did not increase the risk for any tumour, and this finding was independent of the type of GLP-1RA administered and treatment duration. However, our study had many limitations, and further longer term trials with larger samples should be conducted in future to confirm our results.
BACKGROUND AND OBJECTIVE: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel class of injectable antidiabetic drugs. Previous studies indicated that GLP-1RAs (exenatide and liraglutide) might increase the incidence of pancreatitis and pancreatic cancer. Here, we evaluated the clinical safety of once-weekly GLP-1RAs with respect to tumour risk. METHODS: Relevant studies were selected from ClinicalTrials.gov. Randomized controlled trials that reported the incidences of neoplasms were included in our research. Outcomes were calculated as the risk ratio using the Mantel-Haenszel method and fixed-effects model. RESULTS: Our analysis included 26 randomized controlled trials with 16,090 patients. Once-weekly GLP-1RAs did not increase the risk for tumours compared with other antidiabetic drugs [risk ratio (RR), 1.02; 95 % confidence interval (CI), 0.74-1.41; p = 0.91]; this finding was independent of the type of GLP-1RA administered (albiglutide, exenatide extended-release and dulaglutide) and duration of the trials (limited to ≥52 weeks). Subgroup analyses revealed that once-weekly GLP-1RAs did not increase tumour risk compared with placebos, exenatide and liraglutide, insulin or oral drugs. Additionally, once-weekly GLP-1RAs did not increase tumour risk in any tissue. CONCLUSIONS: Compared with other antidiabetic drugs, once-weekly GLP-1RAs did not increase the risk for any tumour, and this finding was independent of the type of GLP-1RA administered and treatment duration. However, our study had many limitations, and further longer term trials with larger samples should be conducted in future to confirm our results.
Authors: Michael A Nauck; Markus M Heimesaat; Kai Behle; Jens J Holst; Markus S Nauck; Robert Ritzel; Michael Hüfner; Wolff H Schmiegel Journal: J Clin Endocrinol Metab Date: 2002-03 Impact factor: 5.958
Authors: Lotte Bjerre Knudsen; Lars Wichmann Madsen; Søren Andersen; Kasper Almholt; Anne S de Boer; Daniel J Drucker; Carsten Gotfredsen; Frederikke Lihme Egerod; Anne Charlotte Hegelund; Helene Jacobsen; Søren Dyring Jacobsen; Alan C Moses; Anne-Marie Mølck; Henriette S Nielsen; Jette Nowak; Helene Solberg; Tu D L Thi; Milan Zdravkovic; Ulrik Moerch Journal: Endocrinology Date: 2010-03-04 Impact factor: 4.736
Authors: Orville G Kolterman; Dennis D Kim; Larry Shen; James A Ruggles; Loretta L Nielsen; Mark S Fineman; Alain D Baron Journal: Am J Health Syst Pharm Date: 2005-01-15 Impact factor: 2.637
Authors: John B Buse; Julio Rosenstock; Giorgio Sesti; Wolfgang E Schmidt; Eduard Montanya; Jason H Brett; Marcin Zychma; Lawrence Blonde Journal: Lancet Date: 2009-06-08 Impact factor: 79.321
Authors: Belinda Gier; Aleksey V Matveyenko; David Kirakossian; David Dawson; Sarah M Dry; Peter C Butler Journal: Diabetes Date: 2012-01-20 Impact factor: 9.461